China SXT Pharmaceuticals Inc
NASDAQ:SXTC

Watchlist Manager
China SXT Pharmaceuticals Inc Logo
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
Watchlist
Price: 1.741 USD 8.81% Market Closed
Market Cap: 202m USD

China SXT Pharmaceuticals Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China SXT Pharmaceuticals Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
Operating Income
-$1.7m
CAGR 3-Years
31%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Income
ÂĄ5.1B
CAGR 3-Years
22%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Income
ÂĄ2.5B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Income
ÂĄ8.1B
CAGR 3-Years
47%
CAGR 5-Years
5%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Income
ÂĄ5B
CAGR 3-Years
13%
CAGR 5-Years
4%
CAGR 10-Years
5%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Income
ÂĄ3.7B
CAGR 3-Years
N/A
CAGR 5-Years
203%
CAGR 10-Years
N/A
No Stocks Found

China SXT Pharmaceuticals Inc
Glance View

Market Cap
202m USD
Industry
Pharmaceuticals

China Sxt Pharmaceuticals, Inc. is a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). The company is headquartered in Taizhou, Jiangsu and currently employs 96 full-time employees. The company went IPO on 2019-01-04. The firm develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The firm sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.

SXTC Intrinsic Value
0.12 USD
Overvaluation 93%
Intrinsic Value
Price

See Also

What is China SXT Pharmaceuticals Inc's Operating Income?
Operating Income
-1.7m USD

Based on the financial report for Mar 31, 2025, China SXT Pharmaceuticals Inc's Operating Income amounts to -1.7m USD.

What is China SXT Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-5%

Over the last year, the Operating Income growth was 20%. The average annual Operating Income growth rates for China SXT Pharmaceuticals Inc have been 31% over the past three years , -5% over the past five years .

Back to Top